Envoy Medical’s (COCH) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Envoy Medical (NASDAQ:COCH) in a research note published on Monday,Benzinga reports. They currently have a $18.00 price target on the stock. HC Wainwright also issued estimates for Envoy Medical’s Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($2.61) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.54) EPS, Q4 2027 earnings at ($0.50) EPS and FY2027 earnings at ($2.25) EPS.

Several other research analysts have also recently issued reports on the company. Lake Street Capital increased their price objective on Envoy Medical from $2.50 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, October 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Envoy Medical in a research report on Monday, October 19th. Finally, Loop Capital set a $20.00 target price on Envoy Medical in a report on Monday, July 27th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Envoy Medical currently has a consensus rating of “Hold” and a consensus target price of $21.00.

Envoy Medical Stock Performance

Shares of COCH stock opened at $6.95 on Monday. The company’s 50-day simple moving average is $6.81 and its two-hundred day simple moving average is $6.88. Envoy Medical has a one year low of $3.63 and a one year high of $9.54.

Envoy Medical (NASDAQ:COCH) last issued its earnings results on Thursday, November 5th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.17. Envoy Medical had a negative net margin of 9,026.41% and a negative return on equity of 5,250.23%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.09 million. On average, analysts anticipate that Envoy Medical will post -2.61 EPS for the current fiscal year.

More Envoy Medical News

These are some of the COCH news items that stood out recently:

• Positive Sentiment: Envoy Medical regained compliance with Nasdaq’s $1 minimum-bid-price requirement after its closing bid stayed at or above that level for 10 consecutive trading days, easing a potential listing concern. Article: Envoy Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
• Positive Sentiment: Reported short interest fell 84.4% from mid-October to October 30, to 89,915 shares, or about 1.3% of shares. Less short positioning may ease some potential selling pressure. Article: Envoy Medical Shares Shorted: Short Interest Down 84.4% in October
• Negative Sentiment: HC Wainwright cut its loss forecasts for Q1–Q4 2027 and FY2027; the full-year 2027 estimate worsened to a loss of $2.25 per share from $1.80. It also increased its projected Q4 2026 loss to $0.64 per share from $0.60, tempering the benefit of the improved FY2026 estimate.

About Envoy Medical

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor. The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.